(NASDAQ: RLYB) Rallybio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.
Rallybio's earnings in 2025 is -$14,170,000.On average, 6 Wall Street analysts forecast RLYB's earnings for 2025 to be -$16,517,316, with the lowest RLYB earnings forecast at -$28,979,229, and the highest RLYB earnings forecast at -$9,758,312. On average, 6 Wall Street analysts forecast RLYB's earnings for 2026 to be -$26,009,492, with the lowest RLYB earnings forecast at -$28,607,484, and the highest RLYB earnings forecast at -$20,403,743.
In 2027, RLYB is forecast to generate -$19,389,892 in earnings, with the lowest earnings forecast at -$18,629,504 and the highest earnings forecast at -$19,960,183.